[Prediction of adverse drug reactions based on genomic information]

Nihon Rinsho. 2007 Oct 28:65 Suppl 8:16-21.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • Anti-Infective Agents / adverse effects
  • Anti-Infective Agents / metabolism
  • Antimetabolites, Antineoplastic / adverse effects*
  • Antimetabolites, Antineoplastic / metabolism
  • Antineoplastic Agents, Phytogenic / adverse effects*
  • Antineoplastic Agents, Phytogenic / metabolism
  • Arylamine N-Acetyltransferase / genetics
  • Asian People
  • Azathioprine / adverse effects*
  • Azathioprine / metabolism
  • Camptothecin / adverse effects
  • Camptothecin / analogs & derivatives*
  • Camptothecin / metabolism
  • Cytidine Deaminase / genetics
  • Deoxycytidine / adverse effects
  • Deoxycytidine / analogs & derivatives
  • Deoxycytidine / metabolism
  • Forecasting*
  • Gemcitabine
  • Glucuronosyltransferase / genetics*
  • Humans
  • Irinotecan
  • Mercaptopurine / adverse effects*
  • Mercaptopurine / metabolism
  • Methyltransferases / genetics*
  • Polymorphism, Genetic*
  • Prodrugs / adverse effects*
  • Prodrugs / metabolism
  • Sulfamethoxazole / adverse effects
  • Sulfamethoxazole / metabolism

Substances

  • Anti-Infective Agents
  • Antimetabolites, Antineoplastic
  • Antineoplastic Agents, Phytogenic
  • Prodrugs
  • Deoxycytidine
  • Irinotecan
  • Mercaptopurine
  • Methyltransferases
  • thiopurine methyltransferase
  • Arylamine N-Acetyltransferase
  • NAT2 protein, human
  • UGT1A1 enzyme
  • Glucuronosyltransferase
  • Cytidine Deaminase
  • Sulfamethoxazole
  • Azathioprine
  • Camptothecin
  • Gemcitabine